Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

The Lancet

Volumn 392, Issue 10162, 2018, Pages 2367-2377

  Mease, Philip ^a,b   Coates, Laura C ^c   Helliwell, Philip S ^d   Stanislavchuk, Mykola ^e   Rychlewska Hanczewska, Anna ^f   Dudek, Anna ^g   Abi Saab, Walid ^h   Tasset, Chantal ^h   Meuleners, Luc ^h   Harrison, Pille ^h   Besuyen, Robin ⁱ   Van der Aa, Annegret ^h   Mozaffarian, Neelufar ^j   Greer, Joy M ^j   Kunder, Rebecca ^j   Van den Bosch, Filip ^k,l   Gladman, Dafna D ^m  

^a Swedish/Providence Family Medicine   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY   (Ukraine)

^f Centrum Medyczne HCP   (Poland)

^g Centrum Medyczne MAG   (Poland)

^h GALAPAGOS NV   (Belgium)

ⁱ Galapagos BV   (Netherlands)

^j GILEAD SCIENCES   (United States)

^k GHENT UNIVERSITY HOSPITAL   (Belgium)

^l GHENT UNIVERSITY   (Belgium)

^m UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FILGOTINIB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; JAK1 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE INHIBITOR; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DACTYLITIS; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ENTHESITIS; FEMALE; HEADACHE; HERPES ZOSTER; HIP FRACTURE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MUSCLE FATIGUE; MYALGIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SCREENING TEST; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; FALLING; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; SEVERITY OF ILLNESS INDEX;

ACCIDENTAL FALLS; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEADACHE; HIP FRACTURES; HUMANS; JANUS KINASE 1; JANUS KINASE INHIBITORS; MALE; MIDDLE AGED; NASOPHARYNGITIS; OPPORTUNISTIC INFECTIONS; PNEUMONIA; PYRIDINES; SEVERITY OF ILLNESS INDEX; TRIAZOLES;

EID: 85055135028     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)32483-8     Document Type: Article

References (32)

1. Ogdie, A, Weiss, P, The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 41 (2015), 545–568.
2. Gladman, DD, Antoni, C, Mease, P, Clegg, DO, Nash, P, Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 (2005), ii14–ii17.
3. Peluso, R, Iervolino, S, Vitiello, M, Bruner, V, Lupoli, G, Di Minno, MN, Extra-articular manifestations in psoriatic arthritis patients. Clin Rheumatol 34 (2015), 745–753.
4. Kerschbaumer, A, Baker, D, Smolen, JS, Aletaha, D, The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis 76 (2017), 2038–2045.
5. Gudu, T, Gossec, L, Quality of life in psoriatic arthritis. Exp Rev Clin Immunol 14 (2018), 405–417.
6. D'Angiolella, LS, Cortesi, PA, Lafranconi, A, et al. Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review. PharmacoEconomics 36 (2018), 567–589.
7. Kawalec, P, Malinowski, KP, The indirect costs of psoriatic arthritis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res 15 (2015), 125–132.
8. Gossec, L, Smolen, JS, Ramiro, S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75 (2016), 499–510.
9. Coates, LC, Kavanaugh, A, Mease, PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68 (2016), 1060–1071.
10. Merola, JF, Lockshin, B, Mody, EA, Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum 47 (2017), 29–37.
11. Lebwohl, MG, Bachelez, H, Barker, J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 70 (2014), 871–881.
12. Babon, JJ, Lucet, IS, Murphy, JM, Nicola, NA, Varghese, LN, The molecular regulation of Janus kinase (JAK) activation. Biochem J 462 (2014), 1–13.
13. Meyer, DM, Jesson, MI, Li, X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm, 7, 2010, 41.
14. Mease, P, Hall, S, FitzGerald, O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377 (2017), 1537–1550.
15. Gladman, D, Rigby, W, Azevedo, VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377 (2017), 1525–1536.
16. Wu, D, Yue, J, Tam, LS, Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Rheumatology 57 (2018), 563–571.
17. Van Rompaey, L, Galien, R, van der Aar, EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 191 (2013), 3568–3577.
18. Robin-Jagerschmidt, C, Lavazais, S, Marsais, F, et al. OP0161 the JAK1 selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis. Ann Rheum Dis 76 (2017), 118–119.
19. Kavanaugh, A, Kremer, J, Ponce, L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis 76 (2017), 1009–1019.
20. Westhovens, R, Taylor, PC, Alten, R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis 76 (2017), 998–1008.
21. Genovese, M, Westhovens, R, Meuleners, L, et al. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther, 20, 2018, 57.
22. Vermeire, S, Schreiber, S, Petryka, R, et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389 (2017), 266–275.
23. van der Heijde, D, Baraliakos, X, Gensler, LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet, 2018 published online Oct 22. http://dx.doi.org/10.1016/S0140-6736(18)32463-2.
24. Taylor, W, Gladman, D, Helliwell, P, Marchesoni, A, Mease, P, Mielants, H, Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54 (2006), 2665–2673.
25. Mease, PJ, Woolley, JM, Bitman, B, Wang, BC, Globe, DR, Singh, A, Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 38 (2011), 2461–2465.
26. Winthrop, KL, Yamanaka, H, Valdez, H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66 (2014), 2675–2684.
27. US Food and Drug Administration. FDA Briefing document. NDA 207924 Baricitnib, a Janus kinase (JAK) inhibitor for RA. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm605061.pdf, 2018. (Accessed 28 August 2018)
28. D'Angelo, S, Tramontano, G, Gilio, M, Leccese, P, Olivieri, I, Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol 9 (2017), 21–28.
29. Mease, P, van der Heijde, D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 77 (2018), 890–897.
30. Mease, PJ, van der Heijde, D, Ritchlin, CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76 (2017), 79–87.
31. Nash, P, Ohson, K, Walsh, J, et al. Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis 77 (2018), 690–698.
32. Wells, AF, Edwards, CJ, Kivitz, AJ, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology 57 (2018), 1253–1263.